117 related articles for article (PubMed ID: 8804514)
1. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Naik H; Lehr JE; Pienta KJ
Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
3. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
Naik H; Lehr J; Akhtar A; Pienta K
Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
5. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix.
Pienta KJ; Lehr JE
J Urol; 1993 Jun; 149(6):1622-5. PubMed ID: 8501820
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
8. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of prostate cancer growth by estramustine and colchicine.
Fakih M; Yagoda A; Replogle T; Lehr JE; Pienta KJ
Prostate; 1995 Jun; 26(6):310-5. PubMed ID: 7784270
[TBL] [Abstract][Full Text] [Related]
10. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
de Souza PL; Cooper MR; Imondi AR; Myers CE
Clin Cancer Res; 1997 Feb; 3(2):287-94. PubMed ID: 9815685
[TBL] [Abstract][Full Text] [Related]
11. Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
Dimopoulos MA; Panopoulos C; Bamia C; Deliveliotis C; Alivizatos G; Pantazopoulos D; Constantinidis C; Kostakopoulos A; Kastriotis I; Zervas A; Aravantinos G; Dimopoulos C
Urology; 1997 Nov; 50(5):754-8. PubMed ID: 9372887
[TBL] [Abstract][Full Text] [Related]
12. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
[TBL] [Abstract][Full Text] [Related]
14. Mechanism based chemotherapy for prostate cancer.
Sheridan VR; Tew KD
Cancer Surv; 1991; 11():239-54. PubMed ID: 1841754
[TBL] [Abstract][Full Text] [Related]
15. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
16. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
Naik HR; Lehr JE; Pienta KJ
Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
[TBL] [Abstract][Full Text] [Related]
17. The use of estramustine phosphate in the modern management of advanced prostate cancer.
Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
[TBL] [Abstract][Full Text] [Related]
18. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
Pienta KJ; Redman BG; Bandekar R; Strawderman M; Cease K; Esper PS; Naik H; Smith DC
Urology; 1997 Sep; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
[TBL] [Abstract][Full Text] [Related]
20. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]